Bortezomib in the treatment of multiple myeloma

Bortezomib in the treatment of multiple myeloma

Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promisin...

Deskribapen osoa

Xehetasun bibliografikoak
Argitaratua izan da:Springer eBooks.
Erakunde egilea: SpringerLink (Online service)
Beste egile batzuk: Ghobrial, Irene M., Richardson, Paul G., Anderson, Kenneth C.
Formatua: Electronic Resource
Hizkuntza:English
Argitaratua: Basel Springer Basel c2011.
Gaiak:
Multiple myeloma > Treatment.
Multiple myeloma > Chemotherapy.
Antineoplastic agents.
Boronic Acids > Therapeutic use.
Multiple myeloma > Drug therapy.
Antineoplastic agents > Therapeutic use.
Protease inhibitors > Therapeutic use.
Proteasome endopeptidase complex > Antagonists & inhibitors.
Pyrazines > Therapeutic use.
Electronic books.
Sarrera elektronikoa:Available for University of the Philippines Diliman via SpringerLink. Click here to access